Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Asp-3026. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK known ✓ | Q9UM73 | 17/20 | 1.00 |
| ▸ | INSR | P06213 | 6/20 | 1.00 |
| ▸ | IGF1R | P08069 | 6/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 3/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | ERN1 | O75460 | 2/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | HCK | P08631 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | FER | P16591 | 2/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asp-3026 SCHEMBL31142530 | 1.00 | ALK (1.00) | ALKINSRIGF1REGFRPTK2 | |
| Asp-3026 SCHEMBL29354559 | 1.00 | ALK (1.00) | ALKINSRIGF1REGFRPTK2 | |
| Asp-3026 SCHEMBL30090555 | 1.00 | ALK (1.00) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866379 | 0.97 | ALK (0.94) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866342 | 0.95 | ALK (0.91) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866398 | 0.94 | ALK (0.90) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866485 | 0.94 | ALK (0.89) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866656 | 0.94 | ALK (0.88) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL2823904 | 0.94 | ALK (0.88) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866411 | 0.94 | ALK (0.88) | ALKINSRIGF1REGFRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | claimed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | claimed |
| EP-2581370-A1 | CRYSTALS OF DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2013-04-17 | — | — | EP | claimed |
| US-20130059855-A1 | CRYSTAL OF DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | claimed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | claimed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | claimed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024171957-A1 | TRANSPLANTATION OF PITUITARY HORMONE-PRODUCING CELLS | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| EP-4410963-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | Sumitomo Chemical Company, Limited (JP) | 2024-08-07 | — | — | EP | disclosed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | disclosed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | disclosed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | disclosed |
| US-20130059855-A1 | CRYSTAL OF DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059855-A1 | CRYSTAL OF DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059855-A1 | CRYSTAL OF DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| WO-2012102393-A1 | METHOD FOR PRODUCING DI(ARYLAMINO)ARYL COMPOUND, AND SYNTHETIC INTERMEDIATE THEREFOR | アステラス製薬株式会社 (JP) | 2012-08-02 | — | — | WO | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | ALK 900/4885INSR 2791/4885IGF1R 3349/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ALK 3/4885INSR 607/4885IGF1R 47/4885 |
| US-20130059855-A1 | CRYSTAL OF DI(ARYLAMINO)ARYL COMPOUND | EML4, ALK, ERBB4 | ALK 2/4885INSR 488/4885IGF1R 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.